The global leader within intimate healthcare today announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026.
Though polygraph ("lie detector") tests are too unreliable to be admissible in court, physicians may be forced to undergo them in Physician Health Programs
Dr. David Salehani, a top Los Angeles oral and maxillofacial surgeon, is revolutionizing chin and jaw surgeries using Virtual Surgical Planning (VSP), a 3D planning...
Brain Navi has officially landed in Spain!
TAIPEI, Aug.11, 2025 /PRNewswire/ -- Such an achievement has been made possible through the first of many collaborations...
Brain Navi has officially landed in Spain!
TAIPEI, Aug. 11, 2025 /PRNewswire/ -- Such an achievement has been made possible through the first of many...
ROSEMONT, Ill., Aug. 8, 2025 /PRNewswire/ -- (AANA) -- Wisconsin recently enacted legislation that allows more autonomy for Advanced Practice Registered Nurses (APRNs), including...
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed...
Milan, Italy – August 5, 2025 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company, and the developer of REGENERA™ and SOFTAG™ bioresorbable scaffolds for breast reconstruction and tissue marking, has appointed Bill Hunter, MD, as Chairman of its Board of Directors. Dr. Hunter brings more than 30 years of leadership in the medical technology and life sciences sectors. His appointment reflects Tensive’s focus on strengthening its governance and expanding its global network as it accelerates toward pivotal clinical milestones and commercialization in the U.S. and Europe.
ATLANTA, Aug. 1, 2025 /PRNewswire/ -- MiRus has received New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS) for...